DENVER, Colo. (247marketnews.com)– Today’s session is packed with stories that can move quickly. Among the names attracting attention are Kraig Biocraft Laboratories (OTCQB:KBLB), Pacific Biosciences of California (NASDAQ:PACB), Tenon Medical (NASDAQ:TNON), Faraday Future Intelligent Electric (NASDAQ:FFAI), Creative Media & Community Trust Corporation (NASDAQ:CMCT), Lion Group Holding Ltd. (NASDAQ:LGHL), ImmunityBio, Inc. (NASDAQ:IBRX), Change Agents Corporation (NASDAQ:CHGA), Inventiva S.A. (NASDAQ:IVA), and Quantum-Si Incorporated (NASDAQ:QSI).
Kraig Biocraft Laboratories: High-Performance Spider Silk Workout
Kraig Labs (OTCQB:KBLB) put one of its clearest commercialization markers on the board after announcing shipment of its first commercial order of recombinant spider silk yarn to a globally recognized performance sports brand. The custom-engineered yarn was produced to customer specifications under a confidential pilot program and is intended for development into what Kraig describes as a first-of-its-kind performance textile. The company emphasized that the initial quantity is deliberately small, meaning the significance of the shipment is customer validation and product development rather than immediate recurring revenue.
CEO Kim Thompson called the delivery “a huge milestone for Kraig Labs,” emphasizing that high-performance sport represents a demanding environment in which advanced materials have to demonstrate real-world performance. Kraig says its recombinant spider silk is being developed around characteristics including strength, flexibility, toughness and low weight. The company believes performance apparel could provide a highly visible proving ground for those properties.
Billions have been invested in trying to create these superfibers and Kraig Labs seems to have cracked the code.
The commercial shipment follows another major technology milestone. Kraig recently announced completion of its functional and living Atlas Gene Library, which the company says can support development of recombinant spider silks with different characteristics. That matters because a successful materials business ultimately needs more than one interesting fiber: it needs the ability to engineer materials for specific customers and applications.
Pacific Biosciences: New Leadership Meets Lower-Cost Sequencing Push
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is entering a new chapter under CEO Mark Van Oene, who took over as president and chief executive officer on August 5, succeeding Christian Henry after six years of leadership. Van Oene previously served as PacBio's chief operating officer, providing continuity as the company works to expand adoption of its HiFi sequencing technology.
The technology story is also moving forward. PacBio announced that its Vega system would receive SPRQ-Nx chemistry capable of producing up to 90 gigabases of HiFi data per run, compared with 60 gigabases previously. The company said the chemistry would reduce the U.S. list price per run from $1,100 to $995 and lower cost per gigabase by approximately 40%. Those economics are important in sequencing because instrument placement is only part of the business; recurring consumables and the cost of generating data are central to customer adoption.
PacBio's second-quarter 2026 revenue was $39 million, according to the company's August results release, with management highlighting consumables growth and new Revio and Vega placements. The company is also positioning long-read sequencing across human genetics, oncology, infectious disease, agriculture and other research applications.
Tenon: Capital Restructuring Meets Commercial Medical-Device Story
Tenon Medical (NASDAQ:TNON) is a medical-device company focused on sacroiliac-joint fusion, with its Catamaran SIJ Fusion System designed around a single implant placed directly into the SI joint. The company describes Catamaran as a differentiated surgical option for patients with chronic sacroiliac joint pain who have failed conservative treatment.
The immediate September catalyst, however, is financial rather than clinical. Tenon announced an early repayment of approximately $5.16 million of senior convertible promissory notes on September 9, ahead of their September 11 maturity date. The company then completed a warrant-inducement transaction generating approximately $2.87 million in aggregate gross proceeds.
Faraday Future: Robotics Deal Could Transform Corporate Story
Faraday Future Intelligent Electric (NASDAQ:FFAI) introduced one of the most dramatic business-model developments in this group. On September 29, Faraday Future and AIxCrypto Holdings announced additional details surrounding a proposed transaction under which AIxCrypto, which is expected to become FF EAI Robotics Ecosystem (NASDAQ:FFR), would acquire FFAI's robotics assets and businesses at an estimated $200 million valuation. The transaction remains subject to due diligence, definitive agreements, approvals and customary closing conditions.
The proposed transaction would move the robotics operation into a separate Nasdaq-listed platform. According to the companies, the robotics business had launched 24 products across three robot forms, with cumulative EAI device sales and shipments reaching 552 units by the end of August. The companies reported approximately $1.52 million of cumulative revenue and positive product gross margins for the robotics business.
The proposed structure is designed to create a pure-play robotics company built around four components: an EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and an EAI Data Factory.
Creative Media: Preferred Redemptions Keep Capital Structure in Focus
Creative Media & Community Trust Corporation (NASDAQ:CMCT) is operating in a different corner of the small-cap market, with a portfolio and capital structure that make financing activity an important part of the investment narrative. On September 29, the company declared third-quarter dividends on its Series A, Series A1 and Series D preferred stock, payable October 15 to shareholders of record October 5.
At the same time, CMCT has been using common stock in connection with certain preferred-stock redemptions. SEC filings show that the company issued common shares in August and September in connection with redemptions of Series A and Series A1 preferred stock, with conversion prices based on the relevant VWAP calculations.
That creates an important capital-markets component for $CMCT. Preferred dividends can provide an income-oriented element, while redemptions settled in common shares can affect the company's share count and capital structure.
Lion Group: Crypto Treasury and Corporate Restructuring Collide
Lion Group Holding (NASDAQ:LGHL) is pursuing a dramatically different strategy, with digital assets now occupying a prominent position in its corporate narrative. In September, the company disclosed that it continued to hold approximately 195,000 HYPE tokens as part of its digital-asset treasury-management strategy.
The company is also involved in developments surrounding Skyfame Realty Holdings, where Lion Wealth Management entered into an exclusivity agreement relating to a proposed restructuring. Skyfame submitted a resumption proposal to the Hong Kong Stock Exchange and sought an extension of its remedial period, while a creditor scheme meeting is expected in late October or early November.
Lion also completed a share-capital reduction and reorganization during September, following shareholder approval in July and subsequent approval by the Cayman Islands Registrar of Companies. The reorganization changed the company's authorized share-capital structure and related corporate documents.
ImmunityBio: ANKTIVA Revenue Meets Growing Regulatory Pipeline
ImmunityBio (NASDAQ:IBRX) is increasingly becoming a commercial-stage biotechnology story rather than a purely development-stage one. The company reported second-quarter 2026 net product revenue of $50.7 million, up 92% year over year and 15% sequentially. First-half revenue reached $94.8 million, up 121% from the first half of 2025. ImmunityBio said the second quarter represented its eighth consecutive quarter of sequential revenue growth since ANKTIVA's commercial launch.
The regulatory pipeline is expanding alongside the commercial business. FDA accepted ImmunityBio's supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive non-muscle-invasive bladder cancer with papillary disease without CIS and assigned a January 6, 2027 PDUFA target date. The company also received UAE marketing authorization for ANKTIVA across specified bladder-cancer and metastatic non-small-cell-lung-cancer indications.
ImmunityBio is also attempting to strengthen the supply side of its bladder-cancer franchise. The company entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory covering the Tokyo strain of BCG. ImmunityBio said the arrangement could provide another potential BCG source while addressing longstanding U.S. supply issues. The Tokyo strain remains investigational in the United States.
Change Agents: Agentic AI Meets Counter-Drone Ambitions
Change Agents Corporation (NASDAQ:CHGA) has positioned itself at the intersection of agentic artificial intelligence and defense technology. Its business includes AI software offerings while the company has expanded into autonomous air surveillance and counter-unmanned-aircraft systems.
The company is also developing its defense-oriented strategy through Autonomous Air Defense LLC, a wholly owned subsidiary focused on AI-enabled autonomous air defense and counter-UAS technologies. Change Agents has said its Catch-Up platform completed Phase 2 development and entered beta testing.
Inventiva: MASH Program Moving Toward Major Clinical Inflection Point
Inventiva (NASDAQ:IVA) remains one of the more clinically focused names in this group, with its primary development effort centered on lanifibranor for metabolic dysfunction-associated steatohepatitis, or MASH. The company announced on September 2 that it had reached the last-patient visit in its NATiV3 Phase 3 clinical trial, an important step toward the next stage of the program.
The company reported its unaudited first-half 2026 financial results on September 28 and provided a corporate update around the program. Inventiva is also presenting multiple abstracts at the Paris MASH meeting, keeping attention focused on the scientific and clinical development of lanifibranor.
Quantum-Si: Proteus Data Puts New Engine on the Radar
Quantum-Si Incorporated (NASDAQ:QSI) delivered one of the most striking technology updates in the group with interim development data for its next-generation Proteus protein-sequencing platform. At the 2026 World HUPO Congress, Quantum-Si reported that Proteus outperformed its commercially available Platinum Pro system across multiple sequencing metrics, even though the Proteus instrument, consumables, loading protocol and software remain under development.
In a control-peptide study, Proteus produced a median of 30 times more alignments than Platinum Pro from a single chamber and achieved a 4.8-fold lower median false-discovery rate. The company reported a median FDR of 1.36% for Proteus versus 6.58% for Platinum Pro. In protein mixtures, Quantum-Si reported identifying 1.6 to 2.0 times more peptides, while a 24-protein panel detected all 24 proteins compared with an average of 20.3 using Platinum Pro.
CEO Jeff Hawkins called the results “a fundamentally superior platform technology, not simply a larger version of Platinum Pro.” He also stressed that Proteus has not yet been fully optimized and that the company expects additional improvements ahead of launch.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.